Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).

Howard JF Jr, Vu T, Li G, Korobko D, Smilowski M, Liu L, Gistelinck F, Steeland S, Noukens J, Van Hoorick B, Podhorna J, Borgions F, Li Y, Utsugisawa K, Wiendl H, De Bleecker JL, Mantegazza R, ADAPT-SC and ADAPT-SC+ Study Groups

Open source

DOI: 10.1016/j.neurot.2024.e00378
Published: 2024 Sep
Container: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.neurot.2024.e00378,
  title = {Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).},
  author = {Howard JF Jr and Vu T and Li G and Korobko D and Smilowski M and Liu L and Gistelinck F and Steeland S and Noukens J and Van Hoorick B and Podhorna J and Borgions F and Li Y and Utsugisawa K and Wiendl H and De Bleecker JL and Mantegazza R and ADAPT-SC and ADAPT-SC+ Study Groups},
  year = {2024},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  doi = {10.1016/j.neurot.2024.e00378},
  url = {https://doi.org/10.1016/j.neurot.2024.e00378}
}

RIS

TY  - JOUR
TI  - Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
AU  - Howard JF Jr
AU  - Vu T
AU  - Li G
AU  - Korobko D
AU  - Smilowski M
AU  - Liu L
AU  - Gistelinck F
AU  - Steeland S
AU  - Noukens J
AU  - Van Hoorick B
AU  - Podhorna J
AU  - Borgions F
AU  - Li Y
AU  - Utsugisawa K
AU  - Wiendl H
AU  - De Bleecker JL
AU  - Mantegazza R
AU  - ADAPT-SC and ADAPT-SC+ Study Groups
PY  - 2024
JO  - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
DO  - 10.1016/j.neurot.2024.e00378
UR  - https://doi.org/10.1016/j.neurot.2024.e00378
ER  -

APA

Jr, H. J., T, V., G, L., D, K., M, S., L, L., F, G., S, S., J, N., B, V. H., J, P., F, B., Y, L., K, U., H, W., JL, D. B., R, M., & Groups, A. A. A. S. (2024). Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. https://doi.org/10.1016/j.neurot.2024.e00378

Source records

pubmed · retrieved 2026-09-25T23:56:07.642Z
europe-pmc · retrieved 2026-09-25T23:56:07.642Z